<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018250</url>
  </required_header>
  <id_info>
    <org_study_id>MMB4-09-1001 S-12-08</org_study_id>
    <secondary_id>S-12-08/A-15399.2</secondary_id>
    <nct_id>NCT02018250</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)</brief_title>
  <acronym>MMB4(DMS)</acronym>
  <official_title>A Phase 1 Double-Blind, Placebo-Controlled, Single-Center Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intramuscular Administration of a New Oxime, MMB4 DMS Enhanced Formulation (EF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will evaluate escalating dosages of MMB4 DMS to determine its safety when&#xD;
      delivered intramuscularly (i.m.) to the anterior thigh.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to assess safety, tolerability, and PK of MMB4 DMS EF at up to six&#xD;
      cohorts chosen to provide the range required for PK analyses, including assessment of dose&#xD;
      proportionality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2012</start_date>
  <completion_date type="Actual">October 16, 2013</completion_date>
  <primary_completion_date type="Actual">October 16, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events (AE)</measure>
    <time_frame>30 days post-administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety electrocardiogram (ECG) (3-5 lead)</measure>
    <time_frame>Up to 48-hours post administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>Up to 48-hours post administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-Tidal carbon dioxide</measure>
    <time_frame>Up to 48 hours post administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Up to 48 hours post administration</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Observed Cmax</measure>
    <time_frame>Multiple timepoints between 0 and 24 hours</time_frame>
    <description>Samples will be analyzed for MMB4 using a validated high performance liquid chromatography-tandem mass spectrometry (HPLC/MS/MS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Observed Tmax</measure>
    <time_frame>Multiple timepoints between 0 and 24 hours</time_frame>
    <description>Samples will be analyzed for MMB4 using a validated high performance liquid chromatography-tandem mass spectrometry (HPLC/MS/MS). Samples will be evaluated using semi-log plots and characterized using non-compartmental analysis.</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Treatment Against the Lethal Effects of Nerve Agent Intoxication</condition>
  <arm_group>
    <arm_group_label>0.6 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.6 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 mg benzyl alcohol USP/NF and 5 mg methanesulfonic acid adjusted to a pH 2.3 administered intramuscular (i.m.) to the anterior thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.9 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.2 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.2 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.0 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMB4 DMS</intervention_name>
    <description>Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.</description>
    <arm_group_label>0.6 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_label>0.9 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_label>1.2 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_label>1.5 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_label>2.0 mg/kg MMB4 DMS</arm_group_label>
    <arm_group_label>3.0 mg/kg MMB4 DMS</arm_group_label>
    <other_name>1,1'-methylenebis[4-[(hydroxyimino)methyl]-pyridinium] dimethanesulfonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Benzyl alcohol USP/NF and methanesulfonic acid adjusted to a pH 2.3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be generally healthy adult male or female volunteers, 18-to-55 years-of&#xD;
             age;&#xD;
&#xD;
          -  Subjects must be physically fit as determined by physical examination and BMI;&#xD;
&#xD;
          -  Subjects must have BMI of ≥ 19 and ≤ 30 kg/m2, and weight range of 55-85 kg;&#xD;
&#xD;
          -  Subjects must have adequate venous access;&#xD;
&#xD;
          -  Females of child bearing age must not be pregnant or breast-feeding, nor plan to&#xD;
             become pregnant for the duration of the study, and all females must have a negative&#xD;
             serum pregnancy test within 28 days of treatment, and a negative serum pregnancy test&#xD;
             prior to dosing;&#xD;
&#xD;
          -  Females of childbearing potential must have been using adequate contraception, defined&#xD;
             as the use of hormonal (oral, injectable, or implantable) or barrier-method&#xD;
             contraceptives for at least one month prior to drug administration and must agree to&#xD;
             use an adequate method of contraception for at least one month following drug&#xD;
             administration. Women who are lactating will be excluded. Women without childbearing&#xD;
             potential (who have undergone a total hysterectomy or bilateral oophorectomy, have a&#xD;
             history of bilateral tubal ligation, or are two years post-menopausal) are also&#xD;
             eligible;&#xD;
&#xD;
          -  Males must agree to use a barrier form of birth control (i.e., condom with spermicidal&#xD;
             gel) from the time of check-in to the clinical unit to 30 days after exposure to the&#xD;
             study drug;&#xD;
&#xD;
          -  In the opinion of the Investigator, subjects who comply with the protocol and are&#xD;
             likely to complete the study;&#xD;
&#xD;
          -  Subjects must provide written informed consent by signing and dating an IRB-approved&#xD;
             written informed consent before any screening procedures are performed;&#xD;
&#xD;
          -  Subjects must be willing to refrain from donating blood for eight weeks after&#xD;
             completion of the study period;&#xD;
&#xD;
          -  Subjects must be able to read/comprehend English; and&#xD;
&#xD;
          -  Subjects are non-smokers/tobacco/nicotine product users within three months of first&#xD;
             dosing and must have a total lifetime exposure to cigarettes of &lt;15 pack-years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a PK study or any other clinical study currently or within the last&#xD;
             30 days;&#xD;
&#xD;
          -  History or presence of significant cardiovascular, hepatic, hematologic,&#xD;
             gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric&#xD;
             disease that could potentially impact the safety of the subject or metabolism of the&#xD;
             drug;&#xD;
&#xD;
          -  Have an active malignancy or history of metastatic or hematologic malignancy with the&#xD;
             exception of melanoma in situ or basal or squamous cell carcinoma of the skin.&#xD;
             Subjects must be disease-free for ten years;&#xD;
&#xD;
          -  History of glaucoma;&#xD;
&#xD;
          -  History of seizures;&#xD;
&#xD;
          -  History of allergic or untoward reaction to any bispyridinium oximes; or history&#xD;
             allergy to cotton seed oil or history of anaphylactic shock;&#xD;
&#xD;
          -  History of chronic pulmonary disease or current acute pulmonary disease; history of&#xD;
             treatment for asthma or any other reactive airways disease in the past year;&#xD;
&#xD;
          -  Have ongoing drug abuse/dependence (including alcohol); or recent history (over the&#xD;
             past five years) of treatment for alcohol or drug abuse; or a current positive urine&#xD;
             tests for drug abuse;&#xD;
&#xD;
          -  Have consumed grapefruit, grapefruit juice, other grapefruit containing products, or&#xD;
             starfruit within seven days prior to planned dosing;&#xD;
&#xD;
          -  Having taken, within 14 days of planned dosing, any prescription or non-prescription&#xD;
             medication (including home remedies, herbal supplements or nutritional supplements)&#xD;
             unless the Principal Investigator/Sub-Investigator, in consultation with the Sponsor&#xD;
             Medical Monitor, provides a statement justifying that the medication taken will not&#xD;
             impact the results of this study (with rare exceptions taking prescriptions drugs will&#xD;
             be grounds for exclusion);&#xD;
&#xD;
          -  Preexistent renal insufficiency (estimated GFR using a GFR prediction equation &lt;60&#xD;
             mL/min/1.73m^2, and/or other evidence of structural or functional abnormalities (e.g.&#xD;
             PI assessment of the presence of clinically significant hematuria, proteinuria, or&#xD;
             history of abnormalities on renal imaging) and/or abnormal BUN and serum creatinine or&#xD;
             an abnormal urinalysis;&#xD;
&#xD;
          -  Skeletal muscle disease or evidence of skeletal muscle injury based on abnormal (&gt;1.5&#xD;
             x ULN) blood creatine kinase and myoglobin levels;&#xD;
&#xD;
          -  Clinically relevant abnormal physical findings (including vital signs, pulse oximetry,&#xD;
             and transcutaneous or end-tidal PCO2) or laboratory values at the pre-study period&#xD;
             screening assessment that could interfere with the objectives of the study or the&#xD;
             safety of the subject;&#xD;
&#xD;
          -  Clinically relevant ECG abnormalities based on three 12-lead ECGs obtained five&#xD;
             minutes apart;&#xD;
&#xD;
          -  ECG with a PR interval ≥ 200 msec at screening or before dosing;&#xD;
&#xD;
          -  ECG with a QTc interval &gt; 450 msec for males, 470 msec for females (QT interval&#xD;
             corrected with Bazett formula);&#xD;
&#xD;
          -  Supine blood pressure less than 100/55 mmHg at screening or before dosing;&#xD;
&#xD;
          -  Ejection fraction less than 55% on screening echocardiogram;&#xD;
&#xD;
          -  Have spirometry with abnormal FEV1, FVC or FEV1/FVC ratio according to current&#xD;
             American Thoracic Society/European Respiratory Society standards.&#xD;
&#xD;
          -  Have any specified laboratory values (e.g., hematology - complete blood count with&#xD;
             differential, serum chemistry and urinalysis) outside the normal range for age and sex&#xD;
             and deemed clinically significant by the Principal Investigator, within 28 days before&#xD;
             treatment;&#xD;
&#xD;
          -  Have positive tests for hepatitis B surface antigen, hepatitis C, syphilis, human&#xD;
             immunodeficiency virus (HIV) HIV-1 or HIV-2;&#xD;
&#xD;
          -  Have any skin condition that would interfere with injection of study drug; or&#xD;
&#xD;
          -  Donated &gt;480 mL of blood in the last 8 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed S Al-Ibrahim, MD, ChB, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNBL Clinical Pharmacology Center, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>December 27, 2012</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzyl Alcohol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 20, 2019</submitted>
    <returned>October 11, 2019</returned>
    <submitted>June 29, 2021</submitted>
    <returned>July 20, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

